Transcriptome-Wide Profiling of Protein-RNA Interactions by Cross-Linking and Immunoprecipitation Mediated by FLAG-Biotin Tandem Purification
May 18th, 2020
5.7K views
Here we present a modified CLIP-seq protocol called FbioCLIP-seq with FLAG-biotin tandem purification to determine the RNA targets of RNA-binding proteins (RBPs) in mammalian cells.
Overview
This article presents a modified CLIP-seq protocol called Fbio CLIP-seq, which utilizes FLAG-biotin tandem purification to identify RNA targets of RNA-binding proteins (RBPs) in mammalian cells. The method allows for efficient detection of direct protein-bound RNAs without the need for SDS-PAGE and membrane transfer procedures.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Molecular Biology
Background
- RNA-binding proteins (RBPs) play crucial roles in regulating various biological processes.
- Traditional CLIP-seq methods often require isotopes and specific antibodies.
- Fbio CLIP-seq aims to simplify the process of profiling RBPs and their RNA targets.
- This method is particularly useful for studying mammalian cells.
Purpose of Study
- To develop a more efficient method for identifying RNA targets of RBPs.
- To eliminate the need for complex procedures like SDS-PAGE.
- To provide a protocol that can be easily applied in mammalian cell studies.
Methods Used
- Plating of mouse embryonic stem cells in a 10 cm plate.
- Incubation of cells overnight before treatment.
- Treatment with trypsin EDTA to detach cells.
- Utilization of FLAG-biotin tandem purification for RNA isolation.
Main Results
- The Fbio CLIP-seq method successfully profiles RBPs and their RNA targets.
- Demonstrated efficiency in detecting protein-bound RNAs.
- Showed that the method is isotope-free and antibody-free.
- Provided a streamlined approach for studying RNA-protein interactions.
Conclusions
- Fbio CLIP-seq is a valuable tool for researchers studying RBPs in mammalian cells.
- The method enhances the ability to profile RNA interactions without traditional limitations.
- Future applications may expand to various biological contexts and cell types.
Frequently Asked Questions
What is Fbio CLIP-seq?
Fbio CLIP-seq is a modified protocol for identifying RNA targets of RNA-binding proteins using FLAG-biotin tandem purification.
How does Fbio CLIP-seq differ from traditional CLIP-seq?
It is isotope-free and does not require protein-specific antibodies, simplifying the process of RNA isolation.
What type of cells can be used with this method?
The method is designed for use with mammalian cells, specifically mouse embryonic stem cells in this study.
What are the advantages of using Fbio CLIP-seq?
It allows for efficient detection of direct protein-bound RNAs without complex procedures like SDS-PAGE.
Can this method be applied to other biological studies?
Yes, it has potential applications in various biological contexts and cell types beyond those studied here.
Executive Industry Relevance
Direct mapping of protein-RNA interactions is critical for target validation and mechanistic de-risking in early discovery pipelines. The Fbio CLIP-seq method enables transcriptome-wide identification of direct RNA-binding protein targets without reliance on isotopes or protein-specific antibodies, reducing confounding from indirect interactions. This capability enhances predictive confidence and supports risk-adjusted portfolio decisions in RNA-targeted drug discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables transcriptome-wide interrogation of direct protein-RNA interactions for functional target validation.
- Reduces mechanistic ambiguity by eliminating indirect RNA-binding protein contaminants.
- Supports predictive confidence in target engagement and pathway mapping.
- Facilitates triage of RNA-binding proteins based on direct interaction profiles.
Screening & Assay Development
- Provides a standardized, antibody-free workflow for preparing validated protein-RNA complexes.
- Delivers quantitative readouts of direct binding events suitable for downstream screening.
- Improves reproducibility and scalability by removing isotope and antibody dependencies.
- Enables reliable evaluation of compound effects on protein-RNA interactions.
Translational & Preclinical Research
- Aligns with disease-relevant systems by profiling endogenous interactions in mammalian cells.
- Supports continuity from discovery to preclinical validation by mapping direct RNA targets.
- De-risks translational biomarker selection through high-specificity interaction data.
- Facilitates risk-adjusted advancement of RNA-targeted therapeutic programs.
Pipeline & Workflow Integration
The Fbio CLIP-seq method integrates at the interface of early discovery and lead identification, providing direct evidence of protein-RNA interactions for target validation and assay development.
- Discovery Biology: Supports hypothesis testing and pathway clarification by mapping direct RNA-binding protein targets.
- Screening: Delivers reproducible, quantitative outputs for compound screening and assay standardization.
- Analytics: Enables transcriptome-wide comparison of binding patterns and motif enrichment.
- Translational Research: Connects discovery findings to preclinical models by profiling interactions in disease-relevant cell types.
- Enterprise Reuse: Provides a reusable, antibody-independent platform for diverse RNA-binding protein studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Streamlines workflows through antibody-free, isotope-free, and scalable purification steps.
- Strategic Value: Enables more informed go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of RNA-targeted assets.
Implementation Considerations
- Requires expertise in RNA-protein biochemistry and cross-linking techniques.
- Needs access to UV cross-linking, FLAG and streptavidin bead purification, and high-throughput sequencing infrastructure.
- Demands rigorous cross-team standardization for reproducibility and data comparability.
- Adaptable to various mammalian cell models with protocol optimization.
- Potential limitations include requirement for tagged protein expression and careful validation of purification efficiency.
Biopharma FAQs
Why does null hypothesis testing matter for Fbio CLIP-seq target validation?
Null hypothesis testing ensures that observed protein-RNA interactions are statistically significant and not due to background or indirect binding. This strengthens confidence in functional target validation and supports robust decision-making in early discovery. Reliable statistical thresholds help prioritize targets for further development.
How does independent variable isolation fit the FLAG-biotin tandem purification workflow?
The tandem purification workflow isolates direct protein-RNA complexes by removing copurified RNA-binding proteins, ensuring that only the variable of interest—the tagged protein—is analyzed. This isolation reduces confounding and enables precise mapping of direct interactions, supporting mechanistic de-risking.
What do quantitative dependent variable measurements enable in Fbio CLIP-seq?
Quantitative measurements of unique reads and binding site enrichment allow teams to compare interaction strengths and motif preferences across conditions. These outputs enable data-driven prioritization of targets and inform downstream screening and validation strategies.
Why are replication requirements critical for cross-functional collaboration in CLIP-seq studies?
Replication ensures that protein-RNA interaction profiles are reproducible across experiments and teams, supporting data reliability and cross-functional trust. Consistent results facilitate integration of findings into broader discovery and translational workflows.
What statistical analysis capabilities are required before implementing Fbio CLIP-seq data?
Robust statistical analysis is needed to identify enriched motifs, quantify binding site significance, and assess mutation rates in RNA targets. These capabilities are essential for interpreting results, validating targets, and informing portfolio advancement decisions.
